Synergistic Effects of Amikacin With Imipenem and Ciprofloxacin Against Multidrug‐Resistance Uropathogenic Escherichia coli
Canadian Journal of Infectious Diseases and Medical Microbiology · 2026-01 · 2026 (1)
DOI: 10.1155/cjid/3283079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Infectious Diseases and Medical Microbiology, online erschienen am 23.06.2026. Verfasst von Sahar Sadr Moharerpour und 3 weiteren Autor:innen. Beteiligte Einrichtung: Non-Communicable Pediatric Diseases Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran, mubabol.ac.ir. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Babol University of Medical Sciences.
Abstract (Originalsprache)
Introduction
There are limited therapeutic options available for treating aminoglycoside‐ and carbapenem‐resistant Gram‐negative bacteria. Therefore, there is an urgent need for novel effective antimicrobial agents. Numerous studies have reported the enhanced efficacy of antibiotic combinations against multidrug‐resistant (MDR) strains compared to monotherapy. This study aimed to investigate the potential synergistic effects of amikacin in combination with imipenem and ciprofloxacin against clinical isolates of MDR Escherichia coli to identify the most promising antibiotic combinations for treating infections caused by these isolates.
Methods
In this experimental study, 20 MDR E. coli isolates were examined. The minimum inhibitory concentration (MIC) and checkerboard method were determined for amikacin, imipenem, and ciprofloxacin.
Results
MIC determination revealed ciprofloxacin MICs of 4–512 μg/mL, imipenem 0.125–32 μg/mL, and amikacin 1–128 μg/mL. Resistance rates were 55% (11/20) for amikacin, 100% (20/20) for ciprofloxacin, and 55% (11/20) for imipenem. Synergistic effects were observed between amikacin and imipenem in 50% of isolates (10/20) and between amikacin and ciprofloxacin in 40% (8/20), with no antagonistic interactions detected.
Conclusions
The combination of amikacin with imipenem or ciprofloxacin resulted in synergistic and additive effects in some cases. These findings suggest that antibiotic combination therapy could serve as an effective strategy in managing infections caused by antibiotic‐resistant isolates.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Non-Communicable Pediatric Diseases Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran, mubabol.ac.ir.
- Student Research Committee, Babol University of Medical Sciences, Babol, Iran, mubabol.ac.ir.
- Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran, mubabol.ac.ir.
- Department of Laboratory Sciences, School of Allied Medical Sciences, Babol University of Medical Sciences, Babol, Iran, mubabol.ac.ir.
ORCID-Profile: Mehrdad Halaji
Förderung
- Babol University of Medical Sciences
Zitieren
APA
Moharerpour, S. S., Ahmadi Parviji, F., Javadi, K., & Halaji, M. (2026). Synergistic Effects of Amikacin With Imipenem and Ciprofloxacin Against Multidrug‐Resistance Uropathogenic Escherichia coli. Canadian Journal of Infectious Diseases and Medical Microbiology, 2026(1). https://doi.org/10.1155/cjid/3283079
Vancouver
Moharerpour SS, Ahmadi Parviji F, Javadi K, Halaji M. Synergistic Effects of Amikacin With Imipenem and Ciprofloxacin Against Multidrug‐Resistance Uropathogenic Escherichia coli. Canadian Journal of Infectious Diseases and Medical Microbiology. 2026;2026(1). doi:10.1155/cjid/3283079
BibTeX
@article{Moharerpour2026,
author = {Moharerpour, Sahar Sadr and Ahmadi Parviji, Fatemeh and Javadi, Kasra and Halaji, Mehrdad},
title = {Synergistic Effects of Amikacin With Imipenem and Ciprofloxacin Against Multidrug‐Resistance Uropathogenic Escherichia coli},
journal = {Canadian Journal of Infectious Diseases and Medical Microbiology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/cjid/3283079}
}
EUVIMED